Skip to content
Explore Opportunities
How to community invest
About
Community Capital Report
Connect
Explore Opportunities
How to community invest
About
Community Capital Report
Connect
Search
Twitter
Facebook
Instagram
Health & Wellness
Tech
Women
TTC Oncology
TTC Oncology developed TTC-352, a small molecule to fight breast cancer.
Minneapolis,
MN
Investment type:
Equity
(SAFE)
Target raise:
$50,000
- $250,000
Minimum investment:
$100
End date:
Jan 01, 2023
ended
Learn more at
Wefunder
Share
Highlights
Novel mechanism of action therapy for hormone resistant of breast cancer.
Intellectual property protected until 2033.
Safe and well tolerated oral capsule therapy.
Biomarker that identifies breast cancer that will respond well to TTC-352.
Our Story
We have developed new treatment for breast cancer.
Our Ambition
We would like to have our drug, TTC-352 available in pharmacies to help women with breast cancer.